BRAF and malignant colon neoplasm: Here, we wanted to identify RTKs that were potentially activated during treatment with the monoclonal antibody EGFR inhibitor cetuximab in previously identified intermediate cetuximab-sensitive KRAS and BRAF wild-type colon cancer cell lines.